Brii Biosciences (2137) Fundamentals 2026 — Revenue Analysis | SniperIQ

.00 on the HKSE. This SniperIQ fundamentals page covers Brii Biosciences's valuation, profitability (net margin -1124.4%), revenue (¥18M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Brii Biosciences's market cap?

Brii Biosciences (2137) has a market capitalization of approximately HK$721M, trading at HK

.00 on the HKSE. Market cap moves with the live share price.

What is Brii Biosciences's P/E ratio?

Brii Biosciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Brii Biosciences?

Brii Biosciences runs a net profit margin of -1124.4%, a gross margin of 84.8%, and an operating margin of -1534.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Brii Biosciences generate?

Brii Biosciences reported revenue of ¥18M for fiscal year 2025, with net income of -¥217M and earnings per share (EPS) of -0.3. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Brii Biosciences pay a dividend?

Brii Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Brii Biosciences financially healthy?

Brii Biosciences carries a debt-to-equity ratio of 0.00x and a current ratio of 60.73x, with a market beta of 1.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Brii Biosciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Brii Biosciences (2137) the key facts are: market cap HK$721M, revenue ¥18M, 52-week range 0.92-2.54. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.